Form 4: Guided Therapeutics Director Acquires Shares Through Dividend Conversion
SEC Form 4 Filing
Director John E. Imhoff acquired 35,312 shares of Guided Therapeutics Inc. common stock through the conversion of accrued dividends on Series D preferred stock.
Summary
- On January 17, 2025, John E. Imhoff, a director of Guided Therapeutics Inc., acquired 35,312 shares of common stock.
- The acquisition was a result of the payment of accrued dividends on the director's Series D preferred stock.
- The conversion price was $0.1593 per share.
- Following the transaction, Imhoff beneficially owns 8,762,756 shares of Guided Therapeutics Inc.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing a routine transaction. It doesn't inherently convey positive or negative sentiment.
Industry Context
Form 4 filings are a routine part of regulatory compliance for corporate insiders and provide transparency into their transactions in company stock. This transaction reflects the conversion of preferred stock dividends into common stock, a fairly standard financial procedure.
Key Dates
| Date | Description |
|---|---|
| 01/17/2025 | Date of transaction: John E. Imhoff acquired shares of common stock. |
| 02/18/2025 | Date of signature on the Form 4 filing. |
Keywords
Form 4, Beneficial Ownership, Director, Dividend, Common Stock, Guided Therapeutics Inc, GTHP, Imhoff
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.